keyword
MENU ▼
Read by QxMD icon Read
search

Ustekinumab crohn's

keyword
https://www.readbyqxmd.com/read/28528528/ustekinumab-a-review-in-moderate-to-severe-crohn-s-disease
#1
Yvette N Lamb, Sean T Duggan
Ustekinumab (Stelara(®)) has been recently approved in the EU and the USA as intravenous induction and subcutaneous maintenance therapy for adult patients with moderately to severely active Crohn's disease who have failed or were intolerant to treatment with immunomodulators, corticosteroids or at least one tumour necrosis factor (TNF) antagonist. Ustekinumab, a monoclonal antibody to the shared p40 subunit of the proinflammatory interleukin (IL)-12 and IL-23 cytokines, has a unique mechanism of action distinct from that of TNF antagonists...
May 20, 2017: Drugs
https://www.readbyqxmd.com/read/28477389/paradoxical-ulcerative-colitis-during-adalimumab-treatment-of-psoriasis-resolved-by-switch-to-ustekinumab
#2
A G A Kolios, L Biedermann, A Weber, A A Navarini, J Meier, A Cozzio, L E French
Here we report the case of a psoriasis patient who developed an ulcerative colitis (UC) most likely caused by Adalimumab. After cessation of Adalimumab, colitis improved significantly. However, since psoriasis worsened, the patient was switched to Ustekinumab which resulted in complete cessation of colitis. During the two-year follow-up under Ustekinumab therapy no further gastrointestinal complaints occurred. Paradoxical psoriasis manifestations in inflammatory bowel disease (IBD) under TNF-inhibitor therapy have been reported and rarely paradoxical IBD occurred (mostly Crohn's disease) in rheumatologic patients treated with Infliximab or Etanercept...
May 6, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28463854/surgical-rates-in-the-era-of-biological-therapy-up-down-or-unchanged
#3
Pablo Olivera, Antonino Spinelli, Corinne Gower-Rousseau, Silvio Danese, Laurent Peyrin-Biroulet
PURPOSE OF REVIEW: The aim of this review is to summarize data regarding surgical trends in inflammatory bowel disease in the prebiologic and biologic era, with a focus on population-based studies and randomized controlled trials (RCTs). RECENT FINDINGS: There is paucity of data in RCTs regarding surgical rates, with only a few clinical trials reporting them. From the available data, meta-analyses of RCTs have concluded that antitumor necrosis α agents (anti-TNF) reduce surgical rates in ulcerative colitis and Crohn's disease...
May 1, 2017: Current Opinion in Gastroenterology
https://www.readbyqxmd.com/read/28436109/efficiency-of-ustekinumab-in-crohn-s-disease-with-severe-psoriasiform-rash-induced-by-biotherapies-in-an-adolescent
#4
Valérie Bertrand, Abdelaziz El Haite, Delphine Carré
Ustekinumab is approved for the treatment of psoriasis in adolescents and for the treatment of moderate to severe Crohn's disease (CD) in adults, but data are lacking in pediatric CD. We report a case of severe psoriasis induced by biotherapies in an adolescent with CD that improved after switching to ustekinumab (90 mg at weeks 0, 2, and 4 and then every 8 weeks). The patient had not experienced CD relapse after 1 year of follow-up. Ustekinumab can be an alternative therapy for psoriasis induced by biotherapies when conventional treatment fails and can maintain remission of CD...
April 23, 2017: Pediatric Dermatology
https://www.readbyqxmd.com/read/28417496/editorial-accumulating-data-about-ustekinumab-in-refractory-crohn-s-disease-in-real-world-experience
#5
EDITORIAL
S Khorrami, J P Gisbert
No abstract text is available yet for this article.
May 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28384456/ustekinumab-for-crohn-s-disease
#6
Reena Khanna, Waqqas Afif
No abstract text is available yet for this article.
April 3, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28365485/association-between-ustekinumab-trough-concentrations-and-clinical-biomarker-and-endoscopic-outcomes-in-patients-with-crohn-s-disease
#7
Robert Battat, Uri Kopylov, Talat Bessissow, Alain Bitton, Albert Cohen, Anjali Jain, Myriam Martel, Ernest Seidman, Waqqas Afif
BACKGROUND & AIMS: Ustekinumab, an inhibitor of the p40 subunit of interleukins 12 and 23, is an effective treatment for patients with Crohn's disease (CD). Trough concentrations of tumor necrosis factor (TNF) antagonists and presence of anti-drug antibodies are associated with important clinical and endoscopic outcomes. We investigated associations between trough concentrations of ustekinumab and clinical, biomarker, and endoscopic outcomes of real-world patients with CD. METHODS: We recruited 62 patients with CD who were either refractory or intolerant to TNF antagonists, treated with ustekinumab from April 2014 to September 2015...
March 29, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28329588/ustekinumab-for-treatment-of-cutaneous-crohn-s-disease
#8
Rana Abdat, Alina Markova, Francis A Farraye, Michael K Lichtman
Cutaneous Crohn disease (CD) affecting the vulva, perineum, and perianal skin, is a rare entity, which may accompany or precede gastrointestinal CD. Vulvar involvement, if untreated, may ultimately require extensive surgery including vulvectomy to gain control of the disease. Both gastrointestinal and cutaneous CD respond to biologics, which block TNF. In addition, ustekinumab, which targets both IL-12 and IL-23 cytokines, is effective in patients with gastrointestinal CD who fail TNF blockade. However, it is unclear if ustekinumab is effective for cutaneous CD...
October 15, 2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/28328624/long-term-maintenance-of-clinical-endoscopic-and-radiographic-response-to-ustekinumab-in-moderate-to-severe-crohn-s-disease-real-world-experience-from-a-multicenter-cohort-study
#9
Christopher Ma, Richard N Fedorak, Gilaad G Kaplan, Levinus A Dieleman, Shane M Devlin, Nathan Stern, Karen I Kroeker, Cynthia H Seow, Yvette Leung, Kerri L Novak, Brendan P Halloran, Vivian W Huang, Karen Wong, Philip K Blustein, Subrata Ghosh, Remo Panaccione
BACKGROUND: Ustekinumab is a monoclonal antibody targeting interleukins 12 and 23. While effective in clinical trials for Crohn's disease (CD), long-term maintenance of response in the real-world setting is unclear. We aim to assess the efficacy of ustekinumab for maintaining clinical, endoscopic, and radiographic response in CD. METHODS: A retrospective multicenter cohort study was performed on patients with CD achieving steroid-free clinical response to ustekinumab induction, and advanced onto a regularly scheduled maintenance ustekinumab regimen between 2011 and 2016...
May 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28321458/-erratum-to-ustekinumab-for-the-treatment-of-crohn-s-disease-uniti-im-uniti
#10
B Siegmund, S Nitschmann
No abstract text is available yet for this article.
April 2017: Der Internist
https://www.readbyqxmd.com/read/28252210/clinical-endoscopic-and-radiographic-outcomes-with-ustekinumab-in-medically-refractory-crohn-s-disease-real-world-experience-from-a-multicentre-cohort
#11
C Ma, R N Fedorak, G G Kaplan, L A Dieleman, S M Devlin, N Stern, K I Kroeker, C H Seow, Y Leung, K L Novak, B P Halloran, V W Huang, K Wong, P K Blustein, S Ghosh, R Panaccione
BACKGROUND: Ustekinumab is a monoclonal antibody targeting interleukins-12 and -23, with efficacy in Crohn's disease (CD) demonstrated in clinical trials. AIM: To assess the real-world clinical, endoscopic and radiographic response and remission outcomes achieved with ustekinumab in medically-refractory CD. METHODS: A retrospective multicentre cohort study was performed on CD patients receiving ustekinumab between 2011 and 2016. The primary outcome was achievement of clinical and objective steroid-free response and remission at 3, 6 and 12 months...
May 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28247573/review-article-moving-towards-common-therapeutic-goals-in-crohn-s-disease-and-rheumatoid-arthritis
#12
REVIEW
P B Allen, P Olivera, P Emery, D Moulin, J-Y Jouzeau, P Netter, S Danese, B Feagan, W J Sandborn, L Peyrin-Biroulet
BACKGROUND: Crohn's disease (CD) and rheumatoid arthritis are chronic, progressive and disabling conditions that frequently lead to structural tissue damage. Based on strategies originally developed for rheumatoid arthritis, the treatment goal for CD has recently moved from exclusively controlling symptoms to both clinical remission and complete mucosal healing (deep remission), with the final aim of preventing bowel damage and disability. AIM: To review the similarities and differences in treatment goals between CD and rheumatoid arthritis...
March 1, 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28204858/-ustekinumab-for-the-treatment-of-crohn-s-disease-uniti-im-uniti
#13
B Siegmund, S Nitschmann
No abstract text is available yet for this article.
February 15, 2017: Der Internist
https://www.readbyqxmd.com/read/28179246/legionella-pneumophila-pneumonia-possibly-due-to-ustekinumab-therapy-in-a-patient-with-crohn-s-disease
#14
Joaquín Borrás-Blasco, Xavier Cortes, Sergio Fernandez-Martinez, Elvira Casterá, Beatriz Antequera
PURPOSE: A case report of Legionella pneumophila pneumonia associated with off-label use of ustekinumab in a patient with Crohn's disease (CD) is presented. SUMMARY: A 57-year-old man with longstanding CD was hospitalized with a four-day history of fever (38.5 °C), dyspnea, left pleuritic pain, and weight loss (more than 6 kg) about six weeks after beginning treatment with ustekinumab, a human monoclonal antibody approved in the United States for two indications (plaque psoriasis and psoriatic arthritis) and currently under investigation as a potential treatment for CD and other inflammatory disorders...
February 15, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/28175164/p594-ustekinumab-treatment-effectiveness-in-clinical-practice-a-multicentre-retrospective-review-of-long-term-outcomes-in-crohn-s-disease
#15
C R Rowan, A Alakkari, C Moran, J O'Connell, G Cullen, H Mulcahy, C O'Morain, D McNamara, J Leyden, P MacMathuna, A O'Toole, S Patchett, S McKiernan, D Kevans, G A Doherty, B Ryan
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175158/p626-ustekinumab-for-the-treatment-of-perianal-fistulas-in-patients-with-crohn-s-disease
#16
R Battat, T Bessissow, M Strohl, U Kopylov, A Bitton, A Cohen, E Seidman, W Afif
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175147/p549-effect-of-maintenance-ustekinumab-on-corticosteroid-free-clinical-outcomes-in-patients-with-crohn-s-disease
#17
B G Feagan, C Gasink, P Pollack, D Jacobstein, L-L Gao, J Johanns, Y Miao, S Targan, S Ghosh
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28175098/p360-trough-levels-and-antibodies-to-ustekinumab-are-not-correlated-to-response-to-ustekinumab-treatment-in-crohn-s-disease-patients
#18
P Claire, B Severine, D Nicolas, N Maria, D Pierre, B Julien, G Romain, B Medina, L Myriam, P Benjamin
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28174962/dop053-the-fecal-microbiome-as-a-tool-for-monitoring-and-predicting-response-outcomes-in-ustekinumab-treated-anti-tnf%C3%AE-refractory-crohn-s-disease-patients-results-from-the-certifi-study
#19
M K Doherty, C Koumpouras, S E Telesco, C Monast, C Brodmerkel, P D Schloss
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28174941/dop052-molecular-response-to-ustekinumab-in-moderate-to-severe-crohn-s-disease-by-serum-protein-and-biopsy-gene-expression-analysis-results-from-ustekinumab-phase-3-studies
#20
K Li, K Hayden, E Wadman, S Bhagat, S Emrich, D Jacobstein, C Gasink, C Brodmerkel
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
keyword
keyword
44834
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"